Skip to main content
main-content

Neuer Inhalt Free registration

Gain full access to the latest clinical content available from Springer Nature

Editors' pick

13-02-2018 | Acute lymphoblastic leukemia | News

CAR T-cell therapy promising across age groups in refractory ALL setting

Autologous CD19-directed chimeric antigen receptor T-cell therapy leads to high remission rates and durable responses in children, young adults, and adults with refractory acute lymphoblastic leukemia, indicate two reports appearing in The New England Journal of Medicine.

02-02-2018 | Chronic myeloid leukemia | Editorial | Article

Discontinuing tyrosine kinase inhibitors in chronic myeloid leukemia

Tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) can result in prolonged and deep responses in many patients. In such cases, can TKIs be safely discontinued to avoid adverse side effects and costs? Here, Etab Atallah discusses the current issues surrounding TKI discontinuation in CML.

22-01-2018 | Non-small cell lung cancer | Editorial | Collection

Pembrolizumab-chemotherapy combination in non-small cell lung cancer

Two editorials provide differing opinions on using pembrolizumab with pemetrexed and platinum chemotherapy for non-small cell lung cancer. In the first article, Stephen Liu argues for embracing this new treatment option, while in the second, Sally Lau and Natasha Leighl argue for a little more caution.

Gastric cancer care: From evidence to practice

Gastric cancer care

This program was made possible thanks to independent educational sponsorship from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.

Soft tissue sarcoma: What is best practice?

 Soft tissue sarcoma: What is best practice?

This program was made possible thanks to independent educational sponsorship from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.

Latest from across the site

20-02-2018 | Renal cell carcinoma | News

Phase Ib trial shows promising treatment combination for advanced RCC

Axitinib plus pembrolizumab can be tolerated and shows promising antitumor activity in patients with advanced renal cell carcinoma, researchers from an early-stage US trial say.

Source:

Lancet Oncol 2018; Advance online publication

19-02-2018 | FDA | Drug approval | News

approvalsWatch

FDA nod for apalutamide for nonmetastatic CRPC

Details of this decision are a click away

19-02-2018 | Cervical cancer | News

Chemoradiotherapy benefits demonstrated in locally advanced cervical cancer

Cisplatin chemoradiotherapy significantly delays disease recurrence and improves survival compared with radiotherapy alone in women with stage IIIB squamous cell carcinoma of the cervix, phase III study data show.

Source:

JAMA Oncol 2018; Advance online publication

16-02-2018 | FDA | Drug approval | News

approvalsWatch

Abiraterone acetate approved for metastatic castration-sensitive prostate cancer

Read more on this FDA news here

16-02-2018 | Multiple myeloma | News

Denosumab offers alternative to zoledronic acid in multiple myeloma

Phase III study data show that the RANKL-targeting monoclonal antibody denosumab is noninferior to zoledronic acid for the prevention of bone disease in patients with newly diagnosed multiple myeloma.

Source:

Lancet Oncol 2018; Advance online publication

15-02-2018 | Renal cell carcinoma | News

IMmotion151 supports atezolizumab–bevacizumab for untreated metastatic RCC

In patients with previously untreated metastatic renal cell carcinoma, progression-free survival is significantly longer with the combination of atezolizumab and bevacizumab than with sunitinib, phase III study findings indicate.

Source:

ASCO GU 2018; San Francisco, California, USA

Latest from us on Twitter

Updates from oncology organizations

Meet our Advisory Board

image credits